Press • 04.03.2024

Temedica and the World Economic Forum collaborate to highlight the importance of integrated data in personalizing healthcare

Integrating data for health: a revolutionary approach by Temedica and the World Economic Forum

 

We are thrilled to announce a groundbreaking collaboration with the World Economic Forum, featuring our CEO and Founder, Gloria Seibert. The recently published article, "Why integrated data is critical to personalizing healthcare" underscores our commitment to revolutionizing healthcare through data-driven personalization. Gloria's insights into the challenges and solutions in creating a healthcare model that caters to individual patient needs are pioneering. This publication marks a significant milestone in our journey towards a more nuanced and effective healthcare system.

In the article, Gloria advocates for the integration of diverse health data sources to overcome the limitations of current one-size-fits-all healthcare models. By highlighting the importance of a collaborative data ecosystem, she outlines a future where healthcare is as personalized as our digital experiences. This vision aligns with Temedica's mission to leverage technology and data for more precise, patient-centered care.

We are immensely proud of this collaboration and the potential it unlocks for transforming healthcare. Gloria's leadership and innovative approach continue to inspire our team and stakeholders alike, driving us towards a future where every patient's care is as unique as their health journey.

You can find the complete article "Why integrated data is critical to personalizing healthcare" here.

 

About Temedica

Temedica is a health insights company based in Munich. Since 2016, Temedica has been operating Europe's leading ecosystem for real world insights in the healthcare sector. Temedica's mission is to enable personalized and individualized medicine, thereby focusing on patients and their individual needs. The company achieves this by linking health-related data from various sources, which are processed into valuable insights in compliance with the GDPR.

Temedica is backed by a consortium of renowned investors with many years of experience in the biopharmaceutical industry, including the founding investors of BioNTech. For further information, please visit https://temedica.com/.

 

For more information, please contact:

Temedica GmbH
Anna Hauner
Corporate Communications

Phone: +49 (0) 175 4310301

Mail: pr@temedica.com

Stay informed on new healthcare insights!

Subscribe to our newsletter and never miss out on the latest advancements, insights, and events.

Want to enable your commercial teams with real-world insights?